Fecal immunochemical tests appear more sensitive to colorectal cancer and advanced precancerous lesions in men than women, ...

Novel first-generation cell-free DNA blood (cf-bDNA) tests for colorectal cancer (CRC) cost more and are less effective than colonoscopy or stool tests, a new analysis suggests. Researchers estimated ...

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company and its research collaborators presented new data showing the critical role of blood-based testing ...

New blood-based screening tests for colorectal cancer (CRC) offered fewer benefits at higher cost versus other screening options, a cost-effectiveness modeling study suggested. In a comparison against ...

Significant performance improvement seen across all subtypes of advanced precancerous lesions, which are important to detect for potential ...

Please provide your email address to receive an email when new articles are posted on . Newly available noninvasive colorectal cancer tests have opened the doors to an uptick in screening, especially ...

US regulators may soon clear blood-based biomarker tests for colorectal cancer (CRC), expanding potential options for patients seeking more convenient forms of screening. Most recently, Guardant ...

– As presented later this week at the ASCO GI conference, the large case-control validation study of nearly 1,000 samples highlights a head-to-head comparison with the test's first version, which is ...

Mailing mt-sDNA tests to Medicare Advantage enrollees improved CRC screening adherence, with a 49.4% overall adherence rate. Digital outreach, especially combining email and text, significantly ...

First, the agency is reducing the minimum age at which coverage for the following CRC screening tests begins from age 50 years to age 45 or older: Screening colonoscopy continues to have no minimum ...

SimpleScreen CRC is a blood-based screening test designed to detect colorectal cancer and precancerous lesions. The first-generation version received FDA approval in July 2026 and was commercially ...

Freenome, Inc. ( FRNM ), a company that develops blood tests for early cancer detection, announced it will present late-breaking data on an updated version of its SimpleScreen CRC blood-based ...